Evidence map›Paper›PMID 36420221›Full record

ArticleMolecular therapy. Nucleic acids2022

Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype

Núria Catasús, Inma Rosas, Sandra Bonache, Alex Negro, Miguel Torres-Martin, Adrià Plana-Pla, Hector Salvador, Eduard Serra, Ignacio Blanco, Elisabeth Castellanos and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Molecular therapy. Nucleic acids · 2026
    Article
  2. Review
  3. Review
  4. Expansion of Splice-Switching Therapy with Antisense Oligonucleotides.International journal of molecular sciences · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Núria CatasúsClinical Genomics Research Group, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Crta. Canyet, s/n. Badalona, Barcelona 08916, Spain.
Inma RosasClinical Genomics Research Group, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Crta. Canyet, s/n. Badalona, Barcelona 08916, Spain.
Sandra BonacheClinical Genomics Research Group, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Crta. Canyet, s/n. Badalona, Barcelona 08916, Spain.
Alex NegroClinical Genomics Research Group, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Crta. Canyet, s/n. Badalona, Barcelona 08916, Spain.
Miguel Torres-MartinClinical Genomics Research Group, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Crta. Canyet, s/n. Badalona, Barcelona 08916, Spain.
Adrià Plana-PlaDermatology Department, Germans Trias i Pujol University Hospital (HUGTP), Can Ruti Campus, Badalona, Barcelona 08916, Spain.
Hector SalvadorPediatric Oncology Unit, Hospital Sant Joan de Déu, Esplugues, Barcelona, Spain.
Eduard SerraHereditary Cancer Group, Germans Trias i Pujol Research Institute (IGTP-PMPPC), Can Ruti Campus, Badalona, Barcelona 08916, Spain.
Ignacio BlancoClinical Genomics Research Group, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Crta. Canyet, s/n. Badalona, Barcelona 08916, Spain.
Elisabeth CastellanosClinical Genomics Research Group, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Crta. Canyet, s/n. Badalona, Barcelona 08916, Spain.
NF2-related SWN Spanish National Reference Centre HUGTP-ICO-IGTP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NF2-related schwannomatosis (NF2-related SWN) is an autosomal dominant condition caused by loss of function variants in the

Indexed as

actin cytoeskeletonantisense oligomersantisense therapygenotype-phenotype correlationsMerlinMT: oligonucleotides: therapies and applicationsneurofibromatosis type 2NF2_related schwannomatosisphosphorodiamidate morpholino oligomers

Identifiers

PMID36420221
PMCPMC9678674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.